Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Baseline Characteristics of Individuals with Paroxysmal Nocturnal Hemoglobinuria in an App-Based Home-Reported Outcomes Study to Evaluate Disease Burden

David Dingli, Connie Zhang, Samantha McStocker, Amanda Healey, Nicholas Kuypers, Mohin Chanpura, Hiba Anwar, Jincy Paulose, Soyon Lee, Puja Seth, Glorian Yen

Blood (2024) 144 (Supplement 1): 2327.

https://doi.org/10.1182/blood-2024-211194

Published: 2024

Journal Articles

Current Real-World Treatment Landscape for Patients with Paroxysmal Nocturnal Hemoglobinuria in the United States

Sarah Tomassetti, Nicholas Kuypers, Jincy Paulose, Mohin Chanpura, Soyon Lee, Tayler Buchan, Claire Buchan, Jackson Tang, Inkyu Kim, Glorian Yen

Blood (2024) 144 (Supplement 1): 5675.

https://doi.org/10.1182/blood-2024-202528

Published: 2024

Journal Articles

Early Insights into Real-World Iptacopan Use Among Patients with Paroxysmal Nocturnal Hemoglobinuria in the United States: The Apprise-PNH Data Platform

David Dingli, Glorian Yen, Nicholas Kuypers, Jincy Paulose, Mohin Chanpura, Soyon Lee, Joseph Barone, Jacob Stutts, Tayler Buchan, Claire Buchan, Inkyu Kim, Jackson Tang, Anem Waheed

Blood (2024) 144 (Supplement 1): 5668.

https://doi.org/10.1182/blood-2024-194425

Published: 2024

Journal Articles

Real-World Characteristics and Treatment History of Patients with Paroxysmal Nocturnal Hemoglobinuria Initiating Iptacopan in US Administrative Claims Data

Jamile Shammo, Ver Bilano, Sina Noshad, Lincy Geevarghese, Glorian Yen, Jincy Paulose, Rachael Sorg, Marley Boyd, Allison Keshishian, Sonia Kim, Samantha Tomicki, Soyon Lee

Blood (2024) 144 (Supplement 1): 5681.

https://doi.org/10.1182/blood-2024-203611

Published: 2024

Journal Articles

Intravenous Treatment Workflow for Paroxysmal Nocturnal Hemoglobinuria from the Perspective of Nurses and Pharmacists in US Clinical Practices

Daniel Winokur, Brian Mulherin, Abdulraheem Yacoub, Soyon Lee, Ver Bilano, Glorian Yen, Anumaxine Geevarghese, Jincy Paulose, Annie Guerin, Dominick Latremouille-Viau, Rebecca Bungay, Gayatri Marathe, Anem Waheed

Blood (2024) 144 (Supplement 1): 7553.

https://doi.org/10.1182/blood-2024-199147

Published: 2024

Journal Articles

Primary Analysis of Spartan: A Phase 2 Trial to Assess the Efficacy and Safety of Crizanlizumab in Patients with Sickle Cell Disease Related Priapism

Blood (2023) 142 (Supplement 1): 146.

https://doi.org/10.1182/blood-2023-179042

Published: 2023

Journal Articles

Health-Related Quality of Life and Symptom-Specific Functional Impairment Among Patients Treated with Parenterally Administered Complement Inhibitors for Paroxysmal Nocturnal Hemoglobinuria

David Dingli, Avery A. Rizio, Lynne Broderick, Kaitlin LaGasse, Michelle K. Carty, Elise Burton, Shaquilla Gordon, Leslie C. Weigand, Glorian P. Yen, Jincy Paulose, Lincy Geevarghese, Soyon Lee

Blood (2023) 142 (Supplement 1): 5126.

https://doi.org/10.1182/blood-2023-182336

Published: 2023

Journal Articles

Incremental Burden Associated with Dose Escalation in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Complement Inhibitors

Srinivas K. Tantravahi, Dominick Latremouille-Viau, Raj Desai, Soyon Lee, Jincy Paulose, Lincy Geevarghese, Annie Guérin, Shravanthi Seshasayee, Nadia Tabatabaeepour, Glorian P. Yen

Blood (2023) 142 (Supplement 1): 5119.

https://doi.org/10.1182/blood-2023-180759

Published: 2023

Journal Articles

Interim Analysis of a Phase 2 Trial to Assess the Efficacy and Safety of Crizanlizumab in Sickle Cell Disease Patients with Priapism (SPARTAN)

Alan Anderson, Fuad El Rassi, Michael R. DeBaun, Modupe Idowu, Julie Kanter, Soheir Adam, Susanna Curtis, Darla Liles, Biree Andemariam, Morgan L. McLemore, Robert Sheppard Nickel, Poornima Ramadas, Jincy Paulose, Dramane I Laine, Mahmudul Khan, Deepika S. Darbari, Arthur L. Burnett

Blood (2022) 140 (Supplement 1): 1636–1638.

https://doi.org/10.1182/blood-2022-157004

Published: 2022

Journal Articles

Pediatric Hydroxyurea Treatment Patterns, Sickle Cell Disease-Related Complication Rates, and Costs in a Large US Administrative Claims Database: A Retrospective Analysis

Deepa Manwani, Arthur Burnett, Jincy Paulose, Glorian P. Yen, Tanya Burton, Amy Anderson, Sara Wang, Soyon Lee, Santosh L. Saraf

Blood (2021) 138 (Supplement 1): 4055.

https://doi.org/10.1182/blood-2021-147956

Published: 2021

Journal Articles

Frequency of Vaso-Occlusive Crises Is Associated with Health-Related Quality of Life in Pediatric Patients with Sickle Cell Disease: US Cross-Sectional Surveys of Adolescents and Caregivers

Andrew D. Campbell, Avery A. Rizio, Kristen L. McCausland, Serban Iorga, Glorian P. Yen, Jincy Paulose, Soyon Lee

Blood (2021) 138 (Supplement 1): 490.

https://doi.org/10.1182/blood-2021-144937

Published: 2021

Journal Articles

Children in the United States with Sickle Cell Disease Experience Greater Educational Burden Than Those Living in Low/Middle Income and Other High-Income Countries

Fuad El Rassi, John James, Biree Andemariam, Beverley Francis-Gibson, Caterina P Minniti, Jincy Paulose, Tom Bailey, Olivera Rajkovic-Hooley, Ifeyinwa Osunkwo

Blood (2021) 138 (Supplement 1): 3106.

https://doi.org/10.1182/blood-2021-146566

Published: 2021

Journal Articles

Rare Cases of Infusion-Related Reactions (IRRs) Presenting As Pain Events during or after Crizanlizumab Infusion in Patients (Pts) with Sickle Cell Disease (SCD): A Systematic Evaluation of Post-Marketing (PM) Reports

Julie Kanter, Amit Shah, Vikas Joshi, Harshit Mehta, Michael Levine, Uma Arunagiri, Jincy Paulose, Breanne Donohue, Alissa Scalera, Deepa Manwani

Blood (2021) 138 (Supplement 1): 3112.

https://doi.org/10.1182/blood-2021-152362

Published: 2021

Journal Articles

A Systematic Literature Review of the Burden of Central Nervous System Complications for Patients with Sickle Cell Disease

Soyon Lee, Pharm.D., Dave Nellesen, PhD, Sedge Lucas, B.A., Jincy Paulose, MD, Vivien A. Sheehan, MDPhD

Blood (2020) 136 (Supplement 1): 10.

https://doi.org/10.1182/blood-2020-140533

Published: 2020

Journal Articles

A Patient-Centric Approach to Improve the Understanding of Sickle Cell Disease Using Real-World Data

E. Leila Jerome Clay, MD, Miranda Bailey, Dan Drozd, MD MSc, Jincy Paulose, MD, Nicholas Ramscar, MBBS, Kieran Mace, PhD, David Wormser, PhD MSc, MPhil

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-139148

Published: 2020

Journal Articles

A Systematic Literature Review of the Burden of Ischemic Priapism in Patients with Sickle Cell Disease

Dave Nellesen, PhD, Sedge Lucas, BA, Che-Rung Liu, MA., Menaka Bhor, PhD, Jincy Paulose, MD, Arthur Burnett, MD MBA

Blood (2019) 134 (Supplement_1): 3467.

https://doi.org/10.1182/blood-2019-128951

Published: 2019

Journal Articles

A Prospective Phase II, Open-Label, Single-Arm, Multicenter Study to Assess the Efficacy and Safety of SEG101 (Crizanlizumab) in Sickle Cell Disease Patients with Priapism (SPARTAN)

Fuad A El Rassi, MD, Deepika S. Darbari, MD, Arthur Burnett, MD MBA, Jincy Paulose, MD, Dramane I Laine, Das Purkayastha, PhD, Gregory J Kato, MD

Blood (2019) 134 (Supplement_1): 1007.

https://doi.org/10.1182/blood-2019-125790

Published: 2019

Journal Articles

A Multicenter Retrospective Noninterventional Follow-up Study in Patients with Sickle Cell Pain Crisis Who Previously Participated in the Sustain Trial in the United States Successor Study

Nirmish Shah, Ralph Boccia, Walter K. Kraft, Brandon M. Hardesty, Jincy Paulose, Dram Laine, Das Purkayastha, Savita Nandal, Abdullah Kutlar, MD

Blood (2018) 132 (Supplement 1): 4910.

https://doi.org/10.1182/blood-2018-99-111332

Published: 2018

NARROW

Baseline Characteristics of Individuals with Paroxysmal Nocturnal Hemoglobinuria in an App-Based Home-Reported Outcomes Study to Evaluate Disease Burden

Current Real-World Treatment Landscape for Patients with Paroxysmal Nocturnal Hemoglobinuria in the United States

Early Insights into Real-World Iptacopan Use Among Patients with Paroxysmal Nocturnal Hemoglobinuria in the United States: The Apprise-PNH Data Platform

Real-World Characteristics and Treatment History of Patients with Paroxysmal Nocturnal Hemoglobinuria Initiating Iptacopan in US Administrative Claims Data

Intravenous Treatment Workflow for Paroxysmal Nocturnal Hemoglobinuria from the Perspective of Nurses and Pharmacists in US Clinical Practices

Primary Analysis of Spartan: A Phase 2 Trial to Assess the Efficacy and Safety of Crizanlizumab in Patients with Sickle Cell Disease Related Priapism

Health-Related Quality of Life and Symptom-Specific Functional Impairment Among Patients Treated with Parenterally Administered Complement Inhibitors for Paroxysmal Nocturnal Hemoglobinuria

Incremental Burden Associated with Dose Escalation in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Complement Inhibitors

Interim Analysis of a Phase 2 Trial to Assess the Efficacy and Safety of Crizanlizumab in Sickle Cell Disease Patients with Priapism (SPARTAN)

Pediatric Hydroxyurea Treatment Patterns, Sickle Cell Disease-Related Complication Rates, and Costs in a Large US Administrative Claims Database: A Retrospective Analysis

Frequency of Vaso-Occlusive Crises Is Associated with Health-Related Quality of Life in Pediatric Patients with Sickle Cell Disease: US Cross-Sectional Surveys of Adolescents and Caregivers

Children in the United States with Sickle Cell Disease Experience Greater Educational Burden Than Those Living in Low/Middle Income and Other High-Income Countries

Rare Cases of Infusion-Related Reactions (IRRs) Presenting As Pain Events during or after Crizanlizumab Infusion in Patients (Pts) with Sickle Cell Disease (SCD): A Systematic Evaluation of Post-Marketing (PM) Reports

A Systematic Literature Review of the Burden of Central Nervous System Complications for Patients with Sickle Cell Disease

A Patient-Centric Approach to Improve the Understanding of Sickle Cell Disease Using Real-World Data

A Systematic Literature Review of the Burden of Ischemic Priapism in Patients with Sickle Cell Disease

A Prospective Phase II, Open-Label, Single-Arm, Multicenter Study to Assess the Efficacy and Safety of SEG101 (Crizanlizumab) in Sickle Cell Disease Patients with Priapism (SPARTAN)

A Multicenter Retrospective Noninterventional Follow-up Study in Patients with Sickle Cell Pain Crisis Who Previously Participated in the Sustain Trial in the United States Successor Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only